In contrast to conventional therapeutic targeting of cathepsins, our data demonstrate that inhibiting specifically the extracellular fraction of CTSD can be a valuable therapeutic strategy for NAFLD. This evidence concerns the gene CTSD and metabolic dysfunction-associated steatotic liver disease.